Concord Wealth Partners Has $1.27 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Concord Wealth Partners raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 58.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,001 shares of the biopharmaceutical company's stock after buying an additional 739 shares during the period. Concord Wealth Partners' holdings in Regeneron Pharmaceuticals were worth $1,269,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of REGN. Brighton Jones LLC grew its position in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after purchasing an additional 686 shares in the last quarter. Proficio Capital Partners LLC lifted its position in Regeneron Pharmaceuticals by 30.5% during the 4th quarter. Proficio Capital Partners LLC now owns 308 shares of the biopharmaceutical company's stock worth $219,000 after acquiring an additional 72 shares during the last quarter. American Assets Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $427,000. Independent Advisor Alliance raised its position in shares of Regeneron Pharmaceuticals by 117.3% during the fourth quarter. Independent Advisor Alliance now owns 478 shares of the biopharmaceutical company's stock valued at $340,000 after buying an additional 258 shares during the last quarter. Finally, Avantax Advisory Services Inc. raised its position in shares of Regeneron Pharmaceuticals by 33.1% during the fourth quarter. Avantax Advisory Services Inc. now owns 1,624 shares of the biopharmaceutical company's stock valued at $1,157,000 after buying an additional 404 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.4%

REGN stock traded up $2.07 during midday trading on Thursday, reaching $550.00. The company's stock had a trading volume of 989,175 shares, compared to its average volume of 924,248. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The stock has a market cap of $59.38 billion, a PE ratio of 14.00, a price-to-earnings-growth ratio of 2.03 and a beta of 0.33. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The business's 50-day simple moving average is $544.09 and its 200-day simple moving average is $617.21.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the business posted $9.55 earnings per share. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.64%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Analyst Ratings Changes

REGN has been the topic of a number of analyst reports. Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, June 2nd. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Finally, Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $700.00 to $580.00 in a research note on Friday, May 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $823.54.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.